elinhd Profile Banner
Elin Hoffmann Dahl Profile
Elin Hoffmann Dahl

@elinhd

Followers
192
Following
280
Statuses
197

Infectious Diseases @haukeland_no | Former Infectious Diseases Medical Advisor @msfaccess @msfnorway| Views my own

Joined April 2012
Don't wanna be here? Send us removal request.
@elinhd
Elin Hoffmann Dahl
6 months
RT @MSF_access: Why do most people w/ #hepatitis, a liver inflammation that can be deadly, STILL go undiagnosed? 1 reason is unaffordable…
0
11
0
@elinhd
Elin Hoffmann Dahl
8 months
RT @ThiruGeneva: @jamie_love @Manon_Ress @marcuslowx @MohgaKamalYanni @ellenthoen Ellen 't Hoen: "There are no obvious players that can tak…
0
4
0
@elinhd
Elin Hoffmann Dahl
8 months
RT @LMenghaney: @MSF Activism does not come from a bottle. It is fostered in trust independence and partnerships with civil society and tho…
0
29
0
@elinhd
Elin Hoffmann Dahl
2 years
RT @MSF_access: There are two new treatments for Ebola, but why are they not readily available for people most at risk? At #WHA76 this week…
0
7
0
@elinhd
Elin Hoffmann Dahl
2 years
@Craig_A_Spencer @paimadhu @MSF_access @MSFsci @DNDi @DreJoanneLiu @doctorsoumya @GHS @daktari1 @CKyobutungi @PeterHotez @udnore @yodifiji This double standard is still ongoing - especially for mAbs as post-exposure prophylaxis where this is still held back from high-risk community contacts when it’s obvious that this is life saving, could break transmission chains and end an outbreak earlier. Heartbreaking.
0
1
2
@elinhd
Elin Hoffmann Dahl
2 years
RT @paimadhu: The world now has 2 approved treatments for Ebola Q: Guess which country has stockpiled nearly all of them? A: USA Q: Gues…
0
428
0
@elinhd
Elin Hoffmann Dahl
2 years
RT @rozscourse: The blood of an Ebola survivor in DRC led to the discovery of treatment. But now there is no access for people that need th…
0
7
0
@elinhd
Elin Hoffmann Dahl
2 years
If you develop therapeutics for diseases which primarily affect low income settings you have a responsibility to ensure those products actually reach these populations #Ebola @MSF_access @julienpotet
0
5
8
@elinhd
Elin Hoffmann Dahl
2 years
How will we ensure equitable access to #MCM for current and future pandemic pathogens? Some recommendations for #Ebola in #MSF report “Ensuring Access to New Treatments for Ebola Virus Disease” @AfricaCDC @WHOAFRO @jarottingen @MSF_access
0
5
6
@elinhd
Elin Hoffmann Dahl
2 years
Having worked with two other filoviruses #Ebola Sudan and #MarburgVirus during last couple of months in #Uganda and #Tanzania where there are no approved products but promising candidates we need to ensure products reaching patients both pre- and post approval @JaneRuth_Aceng
@Shaillytweeting
Shailly Gupta
2 years
Dr Armand Sprecher, MSF : Biggest missed opportunity missed is in the Ebola therapeutics trial agreement since they didn’t mention about affordability and accessibility of therapeutics for countries in Africa where trial was done.
Tweet media one
0
5
10
@elinhd
Elin Hoffmann Dahl
2 years
Its time #Ebola mAbs are used to their full potential! This includes as post-exposure prophylaxis for high-risk community contacts in future outbreak to lower mortality and break transmission chain to control outbreaks earlier. @MSF_access
@Shaillytweeting
Shailly Gupta
2 years
High risk groups that should have got the drug are being left out because of this already which could have helped in curtailing the transmission.
0
2
6
@elinhd
Elin Hoffmann Dahl
2 years
Important landmark to ensure greater access to bedaquiline - a life saving drug and the backbone of all oral and shorter DR-TB regimens. Activism works. @MSF_access
@MSF_access
MSF Access Campaign
2 years
GOOD NEWS! ⚡ A patent challenge by two tuberculosis (TB) survivors was successful! The Indian Patent Office rejected Johnson & Johnson’s (@JNJNews) attempt to extend its monopoly on the lifesaving TB drug bedaquiline. 🧵👇🏽
Tweet media one
0
1
3
@elinhd
Elin Hoffmann Dahl
2 years
RT @MSF_access: GOOD NEWS! ⚡ A patent challenge by two tuberculosis (TB) survivors was successful! The Indian Patent Office rejected J…
0
41
0
@elinhd
Elin Hoffmann Dahl
2 years
Luckily cases have dropped for #Ebola in Uganda, but therefore looks like we missed the possibility to assess if vaccine candidates work against SUDV. Same goes for therapeutic #mAbs MBP134. We need to move from reactiveness to preparedness in R&D for outbreak-prone diseases!
@MSF_access
MSF Access Campaign
2 years
⚠️ #Ebola outbreak in Uganda: While two licensed Ebola vaccines already exist, neither is effective against the species in Uganda (called SUDV). Trials for an effective #vaccine haven’t been able to take off because of the flawed research & development (R&D) model. 🧵👇🏽
0
0
5
@elinhd
Elin Hoffmann Dahl
2 years
@HelenBranswell @WHO Thanks, @HelenBranswell - any info on how they can start with only 100 doses? 100 doses = 10 rings = 1(-2) infected person. Current numbers 36 cases = 360 rings needed already
0
0
0
@elinhd
Elin Hoffmann Dahl
2 years
RT @jarottingen: Uganda Detects Rare Ebola Strain With No Approved Vaccine, Marburg outbreak ends in Ghana
0
1
0
@elinhd
Elin Hoffmann Dahl
2 years
Years of TB progress have been reversed during covid-19 with rise in deaths first time in more than a decade. Massive need for scale up of diagnosis of TB - but supply delays jeopardize this. @CepheidNews need to prioritize production of TB cartridges!
@MSF_access
MSF Access Campaign
2 years
📢 MSF warns that supply delays of critical #TB test by @CepheidNews will cost lives. Read more 👇
0
0
1
@elinhd
Elin Hoffmann Dahl
3 years
. #Pfizer vaccine: 76p to produce, £22 sales price to governments. Already the most profitable drug in history. Norway must call a halt to this pandemic profiteering and support the #TRIPSwaiver NOW! @jonasgahrstore @AHuitfeldt @ingvildkjerkol @Senterpartiet @SVparti @Raudt
@Shaillytweeting
Shailly Gupta
3 years
Pandemic profiteering by corporates
0
0
7